Roberts, JA;
De Waele, JJ;
Dimopoulos, G;
Koulenti, D;
Martin, C;
Montravers, P;
Rello, J;
Rhodes, A;
Starr, T;
Wallis, SC;
et al.
Roberts, JA; De Waele, JJ; Dimopoulos, G; Koulenti, D; Martin, C; Montravers, P; Rello, J; Rhodes, A; Starr, T; Wallis, SC; Lipman, J
(2012)
DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.
BMC Infect Dis, 12.
p. 152.
ISSN 1471-2334
https://doi.org/10.1186/1471-2334-12-152
SGUL Authors: Rhodes, Andrew
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (212kB) | Preview |
Abstract
BACKGROUND: The clinical effects of varying pharmacokinetic exposures of antibiotics (antibacterials and antifungals) on outcome in infected critically ill patients are poorly described. A large-scale multi-centre study (DALI Study) is currently underway describing the clinical outcomes of patients achieving pre-defined antibiotic exposures. This report describes the protocol. METHODS: DALI will recruit over 500 patients administered a wide range of either beta-lactam or glycopeptide antibiotics or triazole or echinocandin antifungals in a pharmacokinetic point-prevalence study. It is anticipated that over 60 European intensive care units (ICUs) will participate. The primary aim will be to determine whether contemporary antibiotic dosing for critically ill patients achieves plasma concentrations associated with maximal activity. Secondary aims will compare antibiotic pharmacokinetic exposures with patient outcome and will describe the population pharmacokinetics of the antibiotics included. Various subgroup analyses will be conducted to determine patient groups that may be at risk of very low or very high concentrations of antibiotics. DISCUSSION: The DALI study should inform clinicians of the potential clinical advantages of achieving certain antibiotic pharmacokinetic exposures in infected critically ill patients.
Item Type: | Article | ||||||
---|---|---|---|---|---|---|---|
Additional Information: | © Roberts et al.; licensee BioMed Central Ltd. 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | ||||||
Keywords: | Anti-Bacterial Agents, Antifungal Agents, Critical Illness, Drug Monitoring, Europe, Humans, Intensive Care Units, Plasma, Prospective Studies, Treatment Outcome, Plasma, Humans, Critical Illness, Anti-Bacterial Agents, Antifungal Agents, Drug Monitoring, Treatment Outcome, Prospective Studies, Intensive Care Units, Europe, Antibiotic, beta eta-lactam, Glycopeptide, Triazole, Echinocandin, Continuous infusion, Extended infusion, Bolus dosing, Adverse events, Pharmacokinetics, Pharmacodynamics, 0605 Microbiology, 1103 Clinical Sciences, 1108 Medical Microbiology, Microbiology | ||||||
SGUL Research Institute / Research Centre: | Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cell Sciences (INCCCS) |
||||||
Journal or Publication Title: | BMC Infect Dis | ||||||
ISSN: | 1471-2334 | ||||||
Language: | eng | ||||||
Dates: |
|
||||||
Publisher License: | Creative Commons: Attribution 2.0 | ||||||
PubMed ID: | 22768873 | ||||||
Web of Science ID: | WOS:000311719600001 | ||||||
Go to PubMed abstract | |||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/110385 | ||||||
Publisher's version: | https://doi.org/10.1186/1471-2334-12-152 |
Statistics
Actions (login required)
![]() |
Edit Item |